Floatz logo

gpc3 car-t cells

Squamous Cell Lung Cancer

Second Affiliated Hospital of Guangzhou Medical UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Squamous Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Hospital of Shandong University
Phase 4BBB
Carboplatin
zhang yi
Phase 3BBB
Docetaxel
Shanghai JMT-Bio Inc.
Phase 3BBB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB

View all 45 →

Same molecule, other indications

gpc3 car-t cells is also rated in:

CARDormant
CC
Indicative ·
43 / 100
View asset →
GPC3 Gene InactivationDormant
CC
Indicative ·
43 / 100
View asset →
T CellDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →